Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory ...

Genmab A/S(Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY ® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R 2 ) ...
Medindia

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the ...
The Daily Signal

How California’s ‘Teen Takeover’ Crime Trend Is Spreading

Independence Day chaos strikes California as "teen takeovers" fuel crime in affluent neighborhoods, alarming authorities and ...
The Lancet

Inherited retinal degenerations: clinical phenotypes and emerging therapies

Inherited retinal degenerations are a diverse group of genetic disorders that result in progressive vision loss. Advances in ...